A carregar...
Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer
SIMPLE SUMMARY: Monoclonal antibodies targeting PD1/PD-L1 are game changers in the treatment of advanced non-small cell lung cancer (NSCLC), but biomarkers are lacking. We previously reported the prognostic role of splenic volume in digestive cancer and its correlation with the presence of immunosup...
Na minha lista:
| Publicado no: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8234633/ https://ncbi.nlm.nih.gov/pubmed/34208673 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13123020 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|